fool.com · 3 jul

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

gurufocus.com · 2 jul

AstraZeneca PLC (AZN) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 76/100

On July 02, 2026, AstraZeneca PLC (AZN) shares rose 6.1% today to a current price of $195.15. The stock has performed well over the past year, showing a signifi

benzinga.com · 2 jul

Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance

Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc (NYSE:AZN) to jointly develop a novel combination therapy for patients with EGFR-mutated and PD-L1 positive non-small cell lung cancer (NSCLC).

zacks.com · 2 jul

Here's Why Astrazeneca (AZN) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

reuters.com · 2 jul

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

AstraZeneca has entered into a deal ​worth up to $1.77 billion with CSPC ‌Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney diseases, ​the Chinese drugmaker said on ​Thursday.

prnewswire.com · 1 jul

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC).

zacks.com · 1 jul

Why Astrazeneca (AZN) Dipped More Than Broader Market Today

Astrazeneca (AZN) closed at $183.86 in the latest trading session, marking a -3.04% move from the prior day.

zacks.com · 1 jul

AZN vs. ILMN: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Astrazeneca (AZN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?